The latest price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) was reported by Citigroup on August 8, 2024. The analyst firm set a price target for $371.00 expecting MDGL to rise to within 12 months (a possible 53.15% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) was provided by Citigroup, and Madrigal Pharmaceuticals maintained their buy rating.

The last upgrade for Madrigal Pharmaceuticals Inc happened on March 15, 2024 when B. Riley Securities raised their price target to $270. B. Riley Securities previously had a sell for Madrigal Pharmaceuticals Inc.

The last downgrade for Madrigal Pharmaceuticals Inc happened on February 27, 2024 when B. Riley Securities changed their price target from $204 to $155 for Madrigal Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Madrigal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Madrigal Pharmaceuticals was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.

While ratings are subjective and will change, the latest Madrigal Pharmaceuticals (MDGL) rating was a maintained with a price target of $382.00 to $371.00. The current price Madrigal Pharmaceuticals (MDGL) is trading at is $242.25, which is out of the analyst’s predicted range.